The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma

Hematology Journal

Volumn 3, Issue 1, 2002, Pages 43-48

  García Sanz, Ramón ^a   González Fraile, Maria Isabel ^a   Sierra, Magdalena ^a   López, Carlos ^a   González, Marcos ^a   San Miguel, Jesús Fernando ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Cyclophosphamide; Dexamethasone; Multiple myeloma; Thalidomide

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFECTION; MALE; MERALGIA PARESTHETICA; MULTIPLE MYELOMA; MYOPATHY; NEUROPATHY; NEUTROPENIA; PILOT STUDY; RECORDING; SOMNOLENCE; THROMBOCYTOPENIA; VERTIGO; AGED; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; SALVAGE THERAPY; STANDARD; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PILOT PROJECTS; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 85047682765     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200150     Document Type: Article

References (47)

1. Cancer Statistics, 2000
2. Treatment of multiple myeloma
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
5. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy
6. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants
7. CCNU (lomustine), idarubicin and dexamethasone (CIDEX): An effective oral regimen for the treatment of refractory or relapsed myeloma
8. Dexamethasone, all trans retinoic acid and interferon alpha 2a in patients with refractory multiple myeloma
9. Etoposide plus idarubicin and prednisone in refractory or relapsed multiple myeloma. A phase II study
10. A phaseI/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma
11. Modulation of multidrug-resistant multiple myeloma by cyclosporin
12. Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells
13. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma
14. Antitumor activity of thalidomide in refractory multiple myeloma
15. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
16. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
17. Thalidomide in the treatment of relapsed multiple myeloma
18. Thalidomide in patients with advanced myeloma: Survival prognostic factors
19. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
20. Weekly low-dose cyclophosphamide and alternate-day prednisone: An effective low toxicity regimen for advanced myeloma
21. Use a gentle approach for refractory myeloma patients
22. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients
23. Thalidomide with dexamethasone for resistant multiple myeloma
24. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma
25. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
26. Immunophenotype of plasma cells from 'Monoclonal Gammopathy of Undetermined Significance' (MGUS) patients
27. IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases
28. Incidence of chromosome numerical changes in multiple myeloma: A FISH analysis using 15 chromosome specific probes
29. A new staging system for multiple myeloma based on the number of S-phase plasma cells
30. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients
31. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes
32. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
33. Thalidomide in the treatment of cutaneous manifestations of lupus erytematous: Experience in sixteen consecutive patients
34. Thalidomide for the treatment of esophageal aphtous ulcers in patients with human immunodeficiency virus infection
35. Effects of thalidomide on HIV associated wasting syndrome: A randomized, placebo controlled clinical trial
36. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
37. Thalidomide is an inhibitor of angiogenesis
38. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
39. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
40. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
41. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer
42. Thalidomide: A revival story
43. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
44. Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM)
45. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
46. Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma
47. Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD)